The pharmaceutical industries are involved in the development of new monoclonal antibodies that target B7H1 (PD-L1) (97, 98), considering that the blockade of B7H1 seems to induce durable tumor regression and prolonged disease stabilization in patients with advanced cancers in a phase I trial (99). The gene discussed is CD274; the disease is cancer.